{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:09:58Z","timestamp":1792188598486,"version":"4.4.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T00:00:00Z","timestamp":1584921600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.ophtha.2020.03.020","type":"journal-article","created":{"date-parts":[[2020,3,27]],"date-time":"2020-03-27T20:06:02Z","timestamp":1585339562000},"page":"1191-1200","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Long-term Visual Outcomes after Release from Protocol in Patients who Participated in the Inhibition of VEGF in Age-related Choroidal Neovascularisation (IVAN) Trial"],"prefix":"10.1016","volume":"127","author":[{"given":"Rebecca N.","family":"Evans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barnaby C.","family":"Reeves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1322-472X","authenticated-orcid":false,"given":"Dawn","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine Alyson","family":"Muldrew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9624-2615","authenticated-orcid":false,"given":"Chris","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon P.","family":"Harding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usha","family":"Chakravarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2020.03.020_bib1","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","article-title":"Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP)","volume":"120","author":"Rofagha","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.03.020_bib2","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.ophtha.2016.03.045","article-title":"Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the Comparison of Age-Related Macular Degeneration Treatments Trials","volume":"123","author":"Maguire","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.03.020_bib3","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/aos.13522","article-title":"An 8-year follow-up of anti-vascular endothelial growth factor treatment with a treat-and-extend modality for neovascular age-related macular degeneration","volume":"95","author":"Berg","year":"2017","journal-title":"Acta Ophthalmologica"},{"key":"10.1016\/j.ophtha.2020.03.020_bib4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ophtha.2018.07.028","article-title":"Safety and efficacy of anti-vascular endothelial growth factor therapies for neovascular age-related macular degeneration: a Report by the American Academy of Ophthalmology","volume":"126","author":"Bakri","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.03.020_bib5","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.ophtha.2015.05.010","article-title":"Long-term outcomes of treatment of neovascular age-related macular degeneration: data from an observational study","volume":"122","author":"Gillies","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.03.020_bib6","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.ophtha.2013.11.031","article-title":"The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity","volume":"121","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.03.020_bib7","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1016\/j.ophtha.2016.07.037","article-title":"UK Age-Related Macular Degeneration Electronic Medical Record System (AMD EMR) Users Group Report IV: incidence of blindness and sight impairment in ranibizumab-treated patients","volume":"123","author":"Johnston","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.03.020_bib8","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0140-6736(13)61501-9","article-title":"Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial","volume":"382","author":"Chakravarthy","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ophtha.2020.03.020_bib10","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol--a new facility for the measurement of health-related quality of life","volume":"16","year":"1990","journal-title":"Health Policy (Amsterdam, Netherlands)"},{"key":"10.1016\/j.ophtha.2020.03.020_bib11","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1136\/bmj.308.6933.896","article-title":"Correlation, regression, and repeated data: Authors' reply","volume":"308","author":"Bland","year":"1994","journal-title":"BMJ"},{"key":"10.1016\/j.ophtha.2020.03.020_bib13","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ophtha.2018.11.036","article-title":"Characterization of poor visual outcomes of neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor agents","volume":"126","author":"Nguyen","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.03.020_bib14","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.ophtha.2018.01.012","article-title":"Consistent long-term therapy of neovascular age-related macular degeneration managed by 50 or more anti-VEGF injections using a treat-extend-stop protocol","volume":"125","author":"Adrean","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.03.020_bib15","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/j.ophtha.2016.05.002","article-title":"Predictors of outcome in patients with neovascular age-related macular degeneration switched from ranibizumab to 8-weekly aflibercept","volume":"123","author":"Chatziralli","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.03.020_bib16","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/aos.13539","article-title":"Treatment for neovascular age-related macular degeneration in Sweden: outcomes at seven years in the Swedish Macula Register","volume":"95","author":"Westborg","year":"2017","journal-title":"Acta Ophthalmologica"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642020303031?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642020303031?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T14:08:55Z","timestamp":1758982135000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642020303031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":14,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0161642020303031"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2020.03.020","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term Visual Outcomes after Release from Protocol in Patients who Participated in the Inhibition of VEGF in Age-related Choroidal Neovascularisation (IVAN) Trial","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2020.03.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American Academy of OphthalmologyThis is an open access article under the CC BY license (<inter-ref xlink: href=http:\/\/creativecommons.org\/licenses\/by\/4.0\/>http:\/\/creativecommons.org\/licenses\/by\/4.0\/<\/inter-ref>).","name":"copyright","label":"Copyright"}]}}